Xvivo Perfusion AB (0RKL) Stock Statistics & Valuation Metrics

Xvivo Perfusion AB has a market cap or net worth of kr10.12B. The enterprise value is kr9.52B.

Xvivo Perfusion AB has 31,499,470 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xvivo Perfusion AB’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 3.40%.

The current PE Ratio of Xvivo Perfusion AB is 89.46. Xvivo Perfusion AB’s PEG ratio is -3.53.

In the last 12 months, Xvivo Perfusion AB had revenue of 822.41M and earned 172.18M in profits. Earnings per share was 5.47.

In the last 12 months, operating cash flow was 94.45M and capital expenditures -19.70M, giving a free cash flow of 74.75M billion.

Xvivo Perfusion AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xvivo Perfusion AB upcoming earnings date is Jul 11, 2025, TBA Not Confirmed.

Xvivo Perfusion AB as a current ratio of 4.58, with Debt / Equity ratio of 0.00%

In the past 12 months, Xvivo Perfusion AB has paid 27.77M in taxes.

Xvivo Perfusion AB EV to EBITDA ratio is 55.03, with an EV/FCF ratio of -183.50.

Xvivo Perfusion AB has kr315.87M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -kr315.87M billion.

Gross margin is 75.05%, with operating margin of 10.74%, and net profit margin of 20.94%.

The average price target for Xvivo Perfusion AB is kr390.19, which is 11.43% higher than the current price. The consensus rating is Hold